Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy

Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV‐infected patient in Asia are limited. Within a hospital‐based HIV programme in Phnom Penh, Cambodia, we determined the proportion completing IPT and reasons for non‐completion.

[1]  G. Maartens,et al.  Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial , 2014, The Lancet.

[2]  R. Chaisson,et al.  A trial of mass isoniazid preventive therapy for tuberculosis control. , 2014, The New England journal of medicine.

[3]  A. Tenna,et al.  Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[4]  A. Efron,et al.  Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. , 2013, The Lancet. Infectious diseases.

[5]  L. Lynen,et al.  Incidence and risk factors for tuberculosis in HIV-infected patients while on antiretroviral treatment in Cambodia. , 2013, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[6]  J. Kaewkungwal,et al.  Barriers to and Motivations for the Implementation of a Treatment Programme for Latent Tuberculosis Infection using Isoniazid for People Living with HIV, in Upper Northern Thailand , 2013, Global journal of health science.

[7]  Kinley Wangdi,et al.  Global evidence directing regional preventive strategies in Southeast Asia for fighting TB/HIV. , 2013, Journal of infection in developing countries.

[8]  L. Lynen,et al.  Timing of antiretroviral therapy in Cambodian hospital after diagnosis of tuberculosis: impact of revised WHO guidelines. , 2013, Bulletin of the World Health Organization.

[9]  S. Swaminathan,et al.  Efficacy of a Six-Month versus a 36-Month Regimen for Prevention of Tuberculosis in HIV-Infected Persons in India: A Randomized Clinical Trial , 2012, PloS one.

[10]  R. Yadav,et al.  The multi-step process of building TB/HIV collaboration in Cambodia , 2012, Health Research Policy and Systems.

[11]  J. Klausner,et al.  Scale-up of isoniazid preventive therapy in PEPFAR-assisted clinical sites in South Africa. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[12]  J. Klausner,et al.  Survey of isoniazid preventive therapy in South Africa, 2011. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[13]  Truls Østbye,et al.  Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort study , 2012, BMC Public Health.

[14]  P. Phanuphak,et al.  Feasibility and efficacy of isoniazid prophylaxis for latent tuberculosis in HIV-infected clients patients in Thailand. , 2012, AIDS research and human retroviruses.

[15]  L. Lynen,et al.  Incidence of Treatment-Limiting Toxicity with Stavudine-Based Antiretroviral Therapy in Cambodia: A Retrospective Cohort Study , 2012, PloS one.

[16]  F. van Leth,et al.  Comment on: predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia. , 2011, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[17]  A. Apisarnthanarak,et al.  Isoniazid preventive therapy and 4-year incidence of pulmonary tuberculosis among HIV-infected Thai patients. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[18]  K. Castro,et al.  6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial , 2011, The Lancet.

[19]  J. van Griensven,et al.  Predictors of immune recovery and the association with late mortality while on antiretroviral treatment in Cambodia. , 2011, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[20]  C. Morrison,et al.  Acceptability of treatment of latent tuberculosis infection in newly HIV-infected young women in Uganda. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[21]  L. Lynen,et al.  Performance of Abdominal Ultrasound for Diagnosis of Tuberculosis in HIV-Infected Persons Living in Cambodia , 2010, Journal of acquired immune deficiency syndromes.

[22]  A. Grant,et al.  Adverse events with isoniazid preventive therapy: experience from a large trial , 2010, AIDS.

[23]  S. Charalambous,et al.  Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study , 2010, AIDS.

[24]  A. Vernon,et al.  Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana. , 2010, American journal of respiratory and critical care medicine.

[25]  S. Lawn,et al.  Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. , 2010, The Lancet. Infectious diseases.

[26]  S. Lawn,et al.  The HIV-associated tuberculosis epidemic—when will we act? , 2010, The Lancet.

[27]  P. Phanuphak,et al.  An algorithm for tuberculosis screening and diagnosis in people with HIV. , 2010, The New England journal of medicine.

[28]  P. Kilmarx,et al.  Isoniazid Tuberculosis Preventive Therapy in HIV-Infected Adults Accessing Antiretroviral Therapy: A Botswana Experience, 2004-2006 , 2009, Journal of acquired immune deficiency syndromes.

[29]  L. Lynen,et al.  Substituting nevirapine for efavirenz: risk factors for toxicity in nonnaive patients in a resource-constrained setting. , 2009, AIDS.

[30]  R. Chaisson,et al.  Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort , 2009, AIDS.

[31]  P. Munseri,et al.  Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[32]  Kevin O'Relly.  Essential prevention and care interventions for adults and adolescents living with HIV in resource - limited , 2008 .

[33]  Richard D Moore,et al.  The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil , 2007, AIDS.

[34]  B. Stilwell,et al.  Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .

[35]  K. Nelson,et al.  INH preventive therapy among adult HIV-infected patients in Thailand. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[36]  J. Volmink,et al.  Treatment of latent tuberculosis infection in HIV infected persons. , 2004, The Cochrane database of systematic reviews.

[37]  P. Lobue,et al.  Use of isoniazid for latent tuberculosis infection in a public health clinic. , 2003, American journal of respiratory and critical care medicine.

[38]  J. Porter,et al.  Twice weekly tuberculosis preventive therapy in HIV infection in Zambia , 1998, AIDS.

[39]  P. Sawanpanyalert,et al.  Adherence to tuberculosis preventive therapy among HIV‐infected persons in Chiang Rai, Thailand , 1997, AIDS.

[40]  D. McFarland,et al.  Preventive chemotherapy for HIV‐associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre , 1995, AIDS.